Frequently asked questions
The following questions are often asked by people contacting Retina UK.
Search
Search results
Webinar: Get Active with British Blind Sport
Alex Pitts from British Blind Sport talks about the benefits of sport and physical activity and the BBS Have a Go Days and Active at Home programme.
ProQR makes progress with potential treatment for LCA
Despite the challenges of the pandemic, researchers and pharmaceutical companies are still making progress towards delivering new treatments for inherited sight loss.
ProQR clinical trial for Leber’s Congenital Amourosis (LCA) 10
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.
Positive early findings from ProQR trial of USH2A therapy
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.
First clinical trial participant receives CRISPR-based therapy
An American living with Leber congenital amaurosis 10 (LCA10) has become the first clinical trial participant in the world to receive a CRISPR gene editing treatment in vivo (inside the body).
e-Newsletter April 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
e-Newsletter May 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
e-Newsletter January 2026
Our monthly e-Newsletter featuring the latest updates from Retina UK.